Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

allogeneic DNT cells RC1012

A population of off-the-shelf (OTS) healthy, donor-derived CD4 and CD8 double-negative T lymphocytes (allo-DNTs), with potential immunomodulating and anti-leukemic activities. The DNTs are expanded ex vivo in order to enhance their tumor destroying potential. Upon administration of the allo-DNTs RC1012, the receptor type II integral membrane protein (KLRK1; NKG2D) and DNAX accessory molecule 1 (cluster of differentiation 226; CD226; DNAM-1) expressed on the DNTs recognize and bind to their cognate ligands expressed on leukemia cells. Upon binding, the DNTs release interferon-gamma (IFN-g), thereby destroying the tumor cells. NKG2D, a member of the CD94/NKG2 family of C-type lectin-like receptors, and DNAM-1, a member of the immunoglobulin superfamily containing 2 Ig-like domains of the V-set, play a key role in natural killer cell (NK)-mediated tumor cell killing. Certain tumor cells express higher levels of NKG2D and DNAM-1 ligands on their surfaces, thereby increasing their susceptibility to DNT-mediated cell lysis.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:Allo-DNT cells RC1012
Allo-DNTs RC1012
allogeneic DNTs RC1012
allogeneic double-negative T cells RC1012
bi-negative T cells RC1012
CD3+CD4-CD8-T cells RC1012
Code name:RC 1012
RC-1012
RC1012
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search